Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00925925 · ClinicalTrials.gov registry record

Epigenetic Markers of B-Cell Function in Low Birth Weight Infants

A clinical trial, sponsored by University of Utah.

Completed
Registry status
64
Enrollment target

NCT00925925: Completed study, sponsored by University of Utah.

NCT00925925 is a clinical trial that has completed, run by University of Utah. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00925925 has completed, sponsored by University of Utah.

COMPLETED
Registry status
64 participants
Enrollment target

Study Summary

Low birth weight (LBW) status (\< 10% for gestational age at birth) is associated with increased risk for diseases such as type II diabetes mellitus, hypertension, chronic obstructive pulmonary disease and coronary artery disease in adults, and represents one example of the "fetal onset of adult disease" hypothesis. Recent data strongly associates LBW status with impaired innate and adaptive immunity leading to increased risk for severe infections during adolescence or early adulthood. Animal studies suggest that the ratio of certain B lymphocyte subpopulations, the B1a and B1b cells, determines whether deficits in immunity occur. This study will determine the ratio of B1b to B1a lymphocyte subpopulations in the cord blood of infants born LBW in the late preterm to term gestations (\> 34 weeks at birth) and compare those ratios with those of normal birth weight (NBW) controls in a nested case control study design. Furthermore, animal studies suggest that the expression patterns of CD5 and CD19 proteins determines the cellular phenotype of the B lymphocyte, that of a B1a or a B1b cell, and that the regulatory regions controlling their expression are epigenetically vulnerable. The investigators will therefore isolate DNA and RNA from both B lymphocyte subpopulations and determine whether epigenetic changes to the regulatory regions of the genes coding for CD5 and CD19 protein expression occur in LBW lymphocyte subpopulations as compared to the lymphocytes from NBW infants. This proposal will be the first human study to examine epigenetic determination of a maladaptive phenotype following LBW status at birth in a specific cell type leading to a specific impairment of innate and adaptive immunity.

Interventions

  • OTHER Cord blood collection for analysis

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2009-06
Est. Completion 2012-05
University of Utah

818 total trials

What the finished NCT00925925 record still lists

NCT00925925 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Cord blood collection for analysis is the first listed.

NCT00925925 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00925925 about?

NCT00925925 is a clinical study titled "Epigenetic Markers of B-Cell Function in Low Birth Weight Infants". Low birth weight (LBW) status (\< 10% for gestational age at birth) is associated with increased risk for diseases such as type II diabetes mellitus, hypertension, chronic obstructive pulmonary disease and coronary artery disease in adults, and represents one example of the "fetal onset of adult dis...

What is the current status of trial NCT00925925?

This trial is currently completed. The enrollment target is 64 participants. The study started on 2009-06. Estimated completion is 2012-05.

What interventions are being tested in trial NCT00925925?

The interventions under investigation include: Cord blood collection for analysis (OTHER).

Who is sponsoring clinical trial NCT00925925?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00925925, the US trial registry maintained by the National Library of Medicine. NCT00925925 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.